Nutex Health (NUTX) files 8-K for Marcum LLP audit consent

Nutex Health Inc. (NUTX) filed a current report to note that its independent auditor, Marcum LLP, has provided formal consent for its audit report to be used in existing registration statements.

Rhea-AI Filing Summary

Nutex Health Inc. (NUTX) filed a current report to note that its independent auditor, Marcum LLP, has provided formal consent for its audit report to be used in existing registration statements. The consent, filed as Exhibit 23.1, covers Marcum’s report on Nutex Health’s consolidated balance sheet as of December 31, 2023, along with the related consolidated statements of operations, changes in equity and cash flows for the two-year period ended December 31, 2023. That audit report is included in Nutex Health’s Form 10-K/A filed on November 18, 2025. This is a routine step that allows Nutex to continue using its audited financial statements in connection with previously filed registration statements.

8-K Event Classification

Item 8.01 — Other Events

1 item

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Nutex Health Inc. (NUTX) announce in this Form 8-K?

Nutex Health Inc. reported that its auditor, Marcum LLP, has given consent for its audit report on Nutex’s consolidated financial statements to be incorporated by reference into certain previously filed registration statements. The consent is filed as Exhibit 23.1.

Which financial statements are covered by the auditor’s consent for Nutex Health (NUTX)?

The consent covers Marcum LLP’s report on Nutex Health’s consolidated balance sheet as of December 31, 2023 and the related consolidated statements of operations, changes in equity and cash flows for each of the two years in the period ended December 31, 2023.

How is Nutex Health’s Form 10-K/A related to this 8-K filing?

The auditor’s report referenced in the consent is the same report included in Nutex Health’s Form 10-K/A filed on November 18, 2025. This 8-K simply adds the auditor’s consent as an exhibit so that report can be used in existing registration statements.

Who is the independent auditor providing consent for Nutex Health (NUTX)?

The independent auditor is Marcum LLP, and their consent is listed as Exhibit 23.1 – Consent of Marcum LLP in the filing.

Does this Nutex Health 8-K indicate any new transaction or earnings information?

No. The 8-K describes a routine auditor consent related to previously issued audited financial statements and does not announce new transactions or earnings results.

Why is an auditor’s consent important for Nutex Health’s registration statements?

An auditor’s consent allows Nutex Health to incorporate the auditor’s report by reference into its previously filed registration statements so those filings can lawfully rely on the audited financial statements.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/24/2025 - 04:52 PM EST Learn about SEC filing dates

0001479681FALSE00014796812025-11-242025-11-24

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549 

FORM 8-K 

CURRENT REPORT 

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 

Date of Report (Date of earliest event reported): November 24, 2025 

NUTEX HEALTH INC.  

(Exact name of registrant as specified in its charter) 

Delaware			001-41346			11-3363609
(State or Other Jurisdiction  of Incorporation)			(Commission File Number)			(I.R.S. Employer  Identification No.)

  

6030 S. Rice Ave, Suite C, Houston, Texas 77081 

(Address of principal executive offices) (zip code) 

(713) 660-0557 

(Registrant’s telephone number, including area code) 

N/A 

(Former name or former address, if changed since last report) 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: 

☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

☐ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

☐ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

Securities registered pursuant to Section 12(b) of the Act: 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.001 par value

NUTX

The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). 

Emerging growth company ☐ 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01. Other Events.

Included as Exhibit 23.1 is an auditors’ consent to the incorporation by reference into certain previously filed registration statements of their report relating to the consolidated balance sheet of Nutex Health Inc. (the “Company”) as of December 31, 2023, the related consolidated statements of operations, changes in equity and cash flows for each of the two years in the period ended December 31, 2023, and the related notes, which report is included in the Company’s Form 10-K/A filed on November 18, 2025.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No.			Description of Exhibit
23.1			Consent of Marcum LLP

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

Date: November 24, 2025			NUTEX HEALTH INC.
			By:			/s/ Jon C. Bates
						Jon C. Bates  Chief Financial Officer